Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2044-5385

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma ; volume:12 ; number:7 ; day:11 ; month:7 ; year:2022 ; pages:1-4 ; date:7.2022
Blood cancer journal ; 12, Heft 7 (11.7.2022), 1-4, 7.2022

Creator: Derman, Benjamin A.
Jakubowiak, Andrzej J.
Thompson, Michael A.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41408-022-00705-6

URN: urn:nbn:de:101:1-2022091421131652522087

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Derman, Benjamin A.
Jakubowiak, Andrzej J.
Thompson, Michael A.
SpringerLink (Online service)

Other Objects (12)

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease

Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

Have we been qualifying measurable residual disease correctly?

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Incorporating clinical guidelines through clinician decision-making

Measurable residual disease (MRD)-testing in haematological and solid cancers

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease

Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

Have we been qualifying measurable residual disease correctly?

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Incorporating clinical guidelines through clinician decision-making

Measurable residual disease (MRD)-testing in haematological and solid cancers

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease

Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

Have we been qualifying measurable residual disease correctly?

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Incorporating clinical guidelines through clinician decision-making

Measurable residual disease (MRD)-testing in haematological and solid cancers

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease

Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

Have we been qualifying measurable residual disease correctly?

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Incorporating clinical guidelines through clinician decision-making

Measurable residual disease (MRD)-testing in haematological and solid cancers

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease

Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

Have we been qualifying measurable residual disease correctly?

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Incorporating clinical guidelines through clinician decision-making

Measurable residual disease (MRD)-testing in haematological and solid cancers

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease

Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

Have we been qualifying measurable residual disease correctly?

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Incorporating clinical guidelines through clinician decision-making

Measurable residual disease (MRD)-testing in haematological and solid cancers

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Related objects

Reset password